
Delos Capital
Description
Delos Capital is a New York-based private equity firm with a dedicated focus on the lower-middle market. The firm specializes in making control investments in established companies, typically partnering closely with existing management teams to drive growth and operational improvements. Their investment strategy is centered on identifying businesses with strong fundamentals that can benefit from strategic guidance and capital infusion, aiming to create significant long-term value.
The firm targets companies across a range of sectors, including industrials, chemicals, packaging, and business services. Delos Capital seeks out businesses with enterprise values generally ranging from $25 million to $250 million. Within these transactions, their typical equity investment per deal falls between $10 million and $50 million, reflecting their commitment to significant ownership stakes and active involvement in their portfolio companies. This approach allows them to implement comprehensive operational enhancements and pursue strategic growth initiatives.
Delos Capital's value creation strategy extends beyond just capital provision. They leverage their team's extensive industry experience and operational expertise to support management in areas such as market expansion, product development, and efficiency optimization. By focusing on fundamental business improvements and sustainable growth, Delos Capital aims to transform their portfolio companies into stronger, more competitive entities within their respective markets, ultimately generating attractive returns for their investors.
Investor Profile
Delos Capital has backed more than 25 startups, with 2 new investments in the last 12 months alone. The firm has led 8 rounds, about 32% of its total and boasts 5 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series A, Series C rounds (top funding stages).
- Majority of deals are located in United States, Germany, Canada.
- Strong thematic focus on Health Care, Biotechnology, Medical.
- Typical check size: $10M – $50M.
Stage Focus
- Series B (28%)
- Series A (24%)
- Series C (20%)
- Private Equity (12%)
- Series D (8%)
- Debt Financing (4%)
- Series E (4%)
Country Focus
- United States (92%)
- Germany (4%)
- Canada (4%)
Industry Focus
- Health Care
- Biotechnology
- Medical
- Medical Device
- Pharmaceutical
- Therapeutics
- Oncology
- Health Diagnostics
- Manufacturing
- Biopharma
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.